Cytek Biosciences, Inc. · NASDAQ:CTKB
Cytek Biosciences — Investor Presentation (January 2026)
16 slides from Cytek Biosciences's investor presentation, January 2026
Slide 1: Investor Presentation
Investor Presentation January 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek’s expected revenue for the fourth quarter and full ye
Slide 3: Empowering scientific communities with leading cell analysis tools
Empowering scientific communities with leading cell analysis tools 3
Slide 4: Cytek 2025 at a Glance
Cytek 2025 at a Glance (1) Broad Customer Base Validated Technology Platform Strong Financial Profile & Global Presence 3,456 >2,000 ~$201M (2) Units Placed Customers 2025 Total Revenue (est.) >3,200 >70 ~$262M Cytek FSP Peer- Countries Cash & Marketable reviewed Publications Securities 1. All metri
Slide 5: Global Scale and Reach with Diversified Revenue Mix
Global Scale and Reach with Diversified Revenue Mix (1) APAC & % Revenue by Industry USA 50% EMEA(2) 26% 24% ROW (3) Academic and Government-Owned 41% Institutions 59% Pharma and Biotech, Distributors and CROs Seattle Amsterdam Fremont (Headquarters) Wuxi Bethesda Tokyo San Diego Shanghai Singapore
Slide 6: Large and Growing Global Cell Analysis Market Addressable by Flow Cytometry
Large and Growing Global Cell Analysis Market Addressable by Flow Cytometry (1) $5.1B 2025 TAM (2) 8.8% Global CAGR 2025-2032 $9.2B 2032 Forecasted TAM 1. The Market Reports (2025); https://www.themarketreports.com 2. TAM = Total Addressable Market 6
Slide 7: Our Strategic Business Pillars
Our Strategic Business Pillars Instruments Applications Bioinformatics Clinical (1) Performance Reagents Cytek Cloud Regulatory Intelligence Enabler Analysis / AI LDT Harmonization Flexibility Optimization Menu Driven Reliability Functionality Management AI Cost Effective Recurring Revenue Exchanges
Slide 8: Broad Portfolio of Best-in-Class Cell Analysis Tools
Instruments Applications Bioinformatics Clinical Broad Portfolio of Best-in-Class Cell Analysis Tools Aurora Evo Cytek Aurora Aurora Cell Sorter Northern Lights Guava Muse Micro Amnis Reagents Cytek Cloud Services 8
Slide 9: Essential Lab Tools: Analyzer to Sorter Underpinned by FSP Technology
Instruments Applications Bioinformatics Clinical Essential Lab Tools: Analyzer to Sorter Underpinned by FSP Technology Northern Aurora Evo Aurora Lights / Aurora Cell Analyzer Sorter >24 Colors from 1-3 Lasers 50+ Colors from 3-5 Lasers 50+ Colors from 3-5 Lasers Individual Researchers & Clinical La
Slide 10: Reagents & Kits Driving Recurring Revenue Growth
Instruments Applications Bioinformatics Clinical Reagents & Kits Driving Recurring Revenue Growth Reagent revenue Fluorochrome conjugated antibodies used to identify cells of interest grew ~21% y/y in Q3 2025 Multi-color kits and panels give users ready-to-use antibodies and protocols Research Areas
Slide 11: Cytek Cloud: OS Delivering End-to-End Integrated Solution for Cytek Tools
Instruments Applications Bioinformatics Clinical Cytek Cloud: OS Delivering End-to-End Integrated Solution for Cytek Tools Functionalities Simplifies complex research with streamlined experiment workflow Enhanced Panel Design Capabilities Saves researchers days to months in designing complex panels
Slide 12: Preliminary 2025 Revenue Results
Preliminary 2025 Revenue Results (1) Product Revenue ~$62M Service Revenue ~+8% Y/Y 2025 Commentary $52.3 +2% Y/Y $45.6 $41.5 -2% Y/Y Q4 showed meaningful acceleration in -8% Y/Y Y/Y quarterly revenue growth compared to prior quarters in 2025 $38.1 $31.4 $28.1 Driven by: • Continued growth of global
Slide 13: Driving Continuous Technology Innovation
Driving Continuous Technology Innovation Cytek Orion Mixer Tonbo Reagents (3) Cytek Muse® Micro Cell Analyzer Amnis® & Guava® Products (2) DXP Athena® Northern Lights Cytek Aurora Cell Sorter Cytek Aurora Evo System Analyzer StarBright Reagents (1) Analyzer 2016 2018 2021 2023 2025 2017 2020 2022 20
Slide 14: Growth Drivers
Growth in Growth in Flow Innovative installed base Reagents driven cytometry new products to drive Service by expanding market growth 2026 growth market share Growth Drivers Conventional Cytek Cloud to Clinical flow cytometer improve workflows expansion in replacement cycle and utilization EMEA and
Slide 15: Well-positioned for Growth and Profitability
Well-positioned for Growth and Profitability Attractive Financial Profile Growing Recurring Revenue Well-positioned to Global Diversification deliver long-term Technology Platform Reagent and service value through Leader businesses benefitting differentiated Multiple geographies from established and
Slide 16: Thank You
Thank You 16
Cytek Biosciences — Investor Presentation (January 2026) on 6ix